A clinical trial conducted in South Africa and Uganda has revealed promising results for a new HIV prevention drug, lenacapavir. This new pre-exposure prophylaxis (PrEP) drug, administered as a twice-yearly injection, has shown to provide total protection against HIV infection in young women. This trial, known as the Purpose 1 trial, included 5,000 participants and compared the efficacy of lenacapavir with two other daily PrEP pills, Truvada (F/TDF) and Descovy (F/TAF).

Key Findings of the Trial

1. Total Protection: The trial demonstrated that none of the 2,134 women who received lenacapavir contracted HIV, indicating a 100% effectiveness rate. In comparison, 16 of the 1,068 women who took Truvada and 39 of the 2,136 women who took Descovy contracted the virus.

2. Three-Pronged Approach: The trial had three arms, with participants randomly assigned to receive lenacapavir, Truvada, or Descovy. This method ensured a fair comparison of the drug’s effectiveness.

3. Young Women at High Risk: The study focused on young women, particularly in eastern and southern Africa, who are disproportionately affected by new HIV infections and often find daily PrEP regimens difficult to maintain due to various social and structural challenges.

Lenacapavir is a fusion capsid inhibitor, which interferes with the HIV capsid, a protein shell protecting the virus’s genetic material. This prevents the virus from replicating. Administered just under the skin every six months, lenacapavir offers a convenient and effective alternative to daily PrEP pills.

Benefits of Lenacapavir

1. Reduced Stigma and Increased Compliance: Young women often face stigma and logistical challenges in taking daily pills. A twice-yearly injection reduces the need for daily decision-making and increases privacy, which can lead to higher compliance.

2. Enhanced Protection: The trial’s results suggest that lenacapavir offers superior protection against HIV compared to existing daily PrEP options.

3. Minimal Side Effects: The study also aimed to ensure the safety of lenacapavir. The results indicated that it is safe for use, with no significant adverse effects reported.

The Purpose 1 trial will continue in an “open label” phase, where participants will be informed about the treatment they received and offered a choice of PrEP moving forward. A sister trial, Purpose 2, is being conducted among cisgender men, transgender, and nonbinary people who have sex with men in various regions, including Africa.

Gilead Sciences, the drug developer, plans to submit the trial results to regulatory bodies in Uganda, South Africa, and other countries. The World Health Organization (WHO) will review the data and potentially issue recommendations. This step is crucial for the drug’s adoption into national health guidelines.

Ensuring that lenacapavir is affordable and accessible is vital for its widespread adoption. Gilead Sciences has expressed intent to offer licenses to companies that produce generic drugs, which will help reduce costs and increase accessibility in public health sectors.

The breakthrough results of the Purpose 1 trial offer great hope for reducing HIV infections, particularly among young women in high-risk regions. The effectiveness and convenience of lenacapavir as a twice-yearly injection make it a game-changer in HIV prevention. As the drug moves through regulatory and accessibility phases, there is optimism that it will become a widely available and effective tool in the global fight against HIV.

By integrating this new drug into a comprehensive HIV prevention strategy, including self-testing, access to condoms, treatment for sexually transmitted infections, and male circumcision, the goal of significantly reducing new HIV infections and ultimately ending AIDS by 2030 becomes more attainable.